National Research Council of Canada

Yasuo Konishi

Bernard Massie

Peter C K Lau

Alaka Mullick

Torsten Steinmetzer

John DiMaio

Feng Ni

Yuko Tsuda

Joanne Magoon

Suwatchai Jarussophon

Zbigniew Szewczuk

Peter Ck Lau

A catecholamine or related compound having (S)-configuration at &#x3b2;-carbon, a physiologically tolerated salt thereof, a prodrug thereof, a physiologically functional derivative thereof or any mixture thereof and having a lipophilicity greater than (S)-noradrenaline has use as an anti-angiogenic agent. A catecholamine or related compound in which a &#x3b2;-hydroxy group has been modified are also anti-angiogenic. The anti-angiogenic agent is preferably a compound of formula (I) or (II) a physiologically tolerated salt thereof, a prodrug thereof, a physiologically functional derivative thereof or any mixture thereof. 

Use of catecholamines and related compounds as anti-angiogenic agents

The invention relates to a new 'gene-switch' (cumate-inducible switch) for mammalian cells, having a mammalian promoter which has a TATA element and is linked to the coding sequence of CymR. This switch is as useful in the development of expression systems and cell-based assays for functional genomics as in the generation of viral vectors for gene therapy.

DNA for eukaryotic expression of CymR

The invention relates to a new 'gene-switch' (cumate-inducible switch) for mammalian cells. This switch is as useful in the development of expression systems and cell-based assays for functional genomics as in the generation of viral vectors for gene therapy.

Cumate-inducible expression system for eukaryotic cells

Bivalent thrombin inhibitors

A thrombin inhibitor comprising a first bulky hydrophobic portion interacting with the catalytic site of thrombin responsible for proteolysis and a second portion at least maintaining the hydrophobic and acidic character of amino acids 55 to 60 of native hirudin at the C-terminal non-catalytic region of N-acetyl-hirudin45-65. Between the first and second portions is a divalent linker moiety having a chain length of at least 10 carbon atoms. Connecting the first bulky hydrophobic portion and the linker is a peptidomimetic bond. Preferably, the bulky hydrophobic portion comprises at least one amino acid of D-configuration. The compounds are useful in the treatment of thrombotic disorders.

Thrombin inhibitors based on the amino acid sequence of hirudin

Growing community of inventors

Kirkland, Canada

Yasuo Konishi